HC Wainwright Cuts VolitionRX (NYSEAMERICAN:VNRX) Price Target to $1.00

VolitionRX (NYSEAMERICAN:VNRX) had its target price cut by HC Wainwright from $1.50 to $1.00 in a research report sent to investors on Thursday morning,Benzinga reports. They currently have a buy rating on the medical research company’s stock.

A number of other equities analysts have also commented on VNRX. Maxim Group lowered shares of VolitionRX from a “buy” rating to a “hold” rating in a research report on Wednesday, December 3rd. D. Boral Capital reaffirmed a “buy” rating and set a $3.00 target price on shares of VolitionRX in a report on Thursday, March 26th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $2.33.

VolitionRX Stock Performance

VNRX stock opened at $0.17 on Thursday. The company has a fifty day moving average price of $0.22 and a 200-day moving average price of $0.33. The company has a market capitalization of $27.18 million, a P/E ratio of -0.78 and a beta of 1.33. VolitionRX has a 52-week low of $0.17 and a 52-week high of $0.94.

VolitionRX (NYSEAMERICAN:VNRX) last issued its earnings results on Tuesday, March 31st. The medical research company reported ($0.05) EPS for the quarter, hitting the consensus estimate of ($0.05). The company had revenue of $0.45 million during the quarter, compared to the consensus estimate of $0.71 million. As a group, sell-side analysts forecast that VolitionRX will post -0.5 earnings per share for the current fiscal year.

Institutional Trading of VolitionRX

Several institutional investors and hedge funds have recently modified their holdings of the business. Jane Street Group LLC purchased a new position in shares of VolitionRX during the fourth quarter worth about $28,000. Virtu Financial LLC raised its stake in VolitionRX by 166.6% in the fourth quarter. Virtu Financial LLC now owns 108,581 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 67,848 shares in the last quarter. Squarepoint Ops LLC purchased a new stake in VolitionRX in the fourth quarter valued at approximately $34,000. Northwestern Mutual Wealth Management Co. bought a new stake in VolitionRX during the second quarter valued at approximately $52,000. Finally, Silverberg Bernstein Capital Management LLC lifted its position in VolitionRX by 15.6% during the third quarter. Silverberg Bernstein Capital Management LLC now owns 232,082 shares of the medical research company’s stock valued at $157,000 after purchasing an additional 31,300 shares during the last quarter. Hedge funds and other institutional investors own 8.09% of the company’s stock.

About VolitionRX

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.